A5044655947- Breast Cancer Treatment Studies
- Bone health and treatments
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Radiopharmaceutical Chemistry and Applications
- Estrogen and related hormone effects
- Cancer Diagnosis and Treatment
- Global Cancer Incidence and Screening
- Advanced Breast Cancer Therapies
- Cancer Genomics and Diagnostics
- Cervical Cancer and HPV Research
- Bone Metabolism and Diseases
- Economic and Financial Impacts of Cancer
- Health Systems, Economic Evaluations, Quality of Life
- Medication Adherence and Compliance
- Cancer Cells and Metastasis
- Congenital Heart Disease Studies
- Prostate Cancer Treatment and Research
- Neutropenia and Cancer Infections
- Gastrointestinal Tumor Research and Treatment
- Global Health and Surgery
- Brain Metastases and Treatment
- Vitamin D Research Studies
- Bone and Joint Diseases
- Advances in Oncology and Radiotherapy
Bellvitge University Hospital
2024
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori
2014-2023
Istituti di Ricovero e Cura a Carattere Scientifico
2014-2023
Novartis (Switzerland)
2021
Istituti Ospitalieri di Cremona
2012
Cancer Institute (WIA)
2010
Istituto Oncologico Romagnolo
1998-2009
Ospedale degli Infermi
2009
Ospedale Infermi di Rimini
2009
Ospedale G.B. Morgagni - L.Pierantoni
2007
This is a noncomparative, randomized, phase II trial of preoperative taxane-anthracycline in combination with trastuzumab, lapatinib, or combined trastuzumab plus lapatinib patients human epidermal growth factor receptor 2 (HER2) -positive, stage to IIIA operable breast cancer. The primary aim was estimate the percentage pathologic complete response (pCR; no invasive tumor and axillary nodes).In three arms, chemotherapy consisted weekly paclitaxel (80 mg/m(2)) for 12 weeks followed by...
Five-year data of the phase III trial TAM-01 showed that low-dose tamoxifen at 5 mg once daily administered for 3 years in women with intraepithelial neoplasia (IEN) reduced by 52% recurrence invasive breast cancer or ductal carcinoma situ (DCIS), without additional adverse events over placebo. Here, we present 10-year results.We randomly assigned 500 IEN (atypical hyperplasia, lobular [LCIS], hormone-sensitive unknown DCIS) to placebo after surgery irradiation. The primary end point was...
Aims and background Bone metastases are responsible for high morbidity in cancer patients. The frequency of pain other serious complications associated with such depends on the site type lesions preventive therapy. present paper aims to inform scientific community about a new organizational health care model specifically designed patients bone metastases, hope stimulating creation similar initiatives whose goals decrease this pathology, reduce complications, limit psychophysical distress...
Bone metastases are a frequent event in patients with solid tumors. Although great advances have been made the treatment of these patients, identification novel, accurate indicators bone response would greatly facilitate clinical management disease. The receptor activator nuclear factor-κB (RANK)/RANK ligand (RANKL)/osteoprotegerin (OPG) signaling pathway is significantly involved metastasis formation. main aim present study was to evaluate role circulating RANK, RANKL and OPG levels...
Patients with solid cancer frequently develop bone metastases (BM). Zoledronic acid (Zometa®, ZA), routinely used to treat patients BM, acts on osteoclasts and also has antitumor properties. We aimed assess the effect of ZA over time in novel turnover markers (RANK/receptor activator nuclear factor-k B ligand (RANK-L)/ Osteoprotegerin (OPG)) correlate these serum N-terminal telopeptide (NTX). The study prospectively evaluated levels RANK, RANK-L OPG transcripts by real-time PCR NTX...
// Dino Amadori 1 , Patrizia Serra 2 Nestory Masalu 3 Akwilina Pangan Emanuela Scarpi Aloyce Maria Bugingo Deogratias Katabalo Toni Ibrahim 4 Alberto Bongiovanni Giacomo Miserocchi Chiara Spadazzi Liverani Valentina Turri 5 Rosanna Tedaldi Laura Mercatali Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy Unit Biostatistics and Clinical Trials, Bugando Center, Mwanza, Tanzania, Africa Osteoncology Rare Tumors...
Retinoblastoma (Rb) is the most common ocular paediatric malignancy and caused by a mutation of two alleles tumor suppressor gene, RB1. The microenvironment (TME) represents complex system whose function not yet well defined where microvesicles, such as exosomes, play key role in intercellular communication. Micro-RNAs (mRNAs) have emerged important modifiers biological mechanisms involved cancer been able to regulate progression.Co-culture monocytes with retinoblastoma cell lines, showed...
<i>Objective:</i> The chemokine receptor CXCR4 is involved in tumor growth and homing of cancer cells to distant sites. aim our retrospective case-control study was evaluate whether expression more effective than conventional markers (estrogen HER-2) predicting bone relapse breast cancer. <i>Methods:</i> evaluated by immunohistochemical staining paraffin-embedded tissue sections primary cancers from 20 patients with metastases (BM), 10 visceral (VM) no evidence...
Breast cancer is the second leading worldwide. In Tanzania, though it ranks as in women after cervical cancer, hormonal receptor status not carried out routinely patients. Adjuvant therapy given without prior knowledge of receptors and patients can incur unnecessary costs side effects. This study was performed to investigate expression receptors, epidermal growth factor (HER-2) proliferation index breast by Ki-67 a few selected with at referral hospital North-Western Tanzania. The classified...
In this study we want to evaluate the efficacy of yoga practice on dysfunctional stress, inflammation and QOL in breast cancer patients undergoing adjuvant radiotherapy.Patients with stage 0 III were recruited before starting radiotherapy (XRT) randomly assigned group (YG) two times a week during XRT or control (CG). Self-report measures QOL, fatigue sleep quality, blood samples collected at day 1 treatment, 15, end treatment 1, 3 6 months later. Cortisol level, IL6, IL10, IL1RA, TNFα...